Autopsy report · NCT00799110

Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod

“Withdrawal of funding”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months after it had already started.
• Ran for about 17 years 4 months before it stopped.
• 15 participants enrolled.
• Results were posted on the registry 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Beth Israel Deaconess Medical Center

Sponsor type

University, hospital or other

Conditions

Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer

Interventions

GM-CSF; Dendritic Cell/Tumor Fusion Vaccine; imiquimod

Participants

15

Sites

4

Countries

United States

Trials that died the same way

• Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
  “Funding withdrawal” (98% match in meaning)
• Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer
  “Withdrawal of funding support” (91% match in meaning)
• Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
  “Funding Withdrawn” (90% match in meaning)
• Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
  “funding was withdrawn” (85% match in meaning)
• Hydroxychloroquine Efficacy in Chronic Urticaria
  “withdrawn, not funded” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.